Investors Investors

Stock Quote

Stock Quote

12:58 PM EDT on Oct 23

Press Releases

Press Releases

All Releases
Oct 23, 2017
NEW YORK , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. , (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third
Oct 16, 2017
NEW YORK , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that data from several of the Company’s development programs will be
Oct 04, 2017
NEW YORK , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that results from the Company’s Phase 2b study of AZEDRA ® , a
Sep 20, 2017
NEW YORK , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the Cantor Fitzgerald
Aug 31, 2017

Study results show that treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival

Aug 31, 2017
- All Sections of New Drug Application (NDA) Have Been Submitted to the FDA, Except Notification of Pre-Approval Inspection Readiness - -Manufacturer Has Requested Additional Time to Prepare for  Pre-Approval Inspection of the Manufacturing Site - NEW YORK, NY, Aug.
Aug 09, 2017
NDA (New Drug Application) for AZEDRA ® Expected to be Submitted to U.S. Food and Drug Administration (FDA) in August 2017 Results from Phase 2b Study of AZEDRA Accepted for Oral Presentation on September 1 st at 2017 International Symposium on Pheochromocytoma and Paraganglioma (ISP) Data
Jul 26, 2017
NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the second quarter ended June 30, 2017 financial results
Jun 02, 2017
NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today the presentation of two studies highlighting the use of an automated bone scan index (aBSI) in men with
Jun 01, 2017
NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2017 Global
May 04, 2017
Phase 2b Registrational Trial of AZEDRA ® Achieved Primary Endpoint under a Special Protocol Assessment agreement with the FDA; Company on Track to Submit NDA in Mid-2017 Phase 2 Data for PSMA-Targeted Imaging Agent 1404 Published in Online Edition of the Journal of Nuclear Medicine ; Phase 3
Apr 27, 2017
NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first quarter ended
Apr 20, 2017
NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that data from a prospective biomarker analysis of a Phase 3 study using Progenics'
Mar 30, 2017
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, will present at the 16th Annual Needham Healthcare
Mar 30, 2017
- Novel, targeted radiotherapeutic for malignant and/or recurrent pheochromocytoma and paraganglioma — - Study achieves primary endpoint - - Secondary endpoint shows favorable tumor response to therapy - - Company to submit NDA in mid-2017 - -Conference call at 8:30 a.m.
Mar 24, 2017
NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the publication of previously-reported results from the Phase 2 study of 1404 in the
Mar 09, 2017
Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Expected First Quarter 2017 Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent 1404 Initiated Phase 2/3 Trial of PyL™ Imaging Agent In February 2017,
Feb 23, 2017
NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the fourth quarter and year
Feb 14, 2017
NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that enrollment of an investigator initiated Phase 1 clinical trial with
Feb 08, 2017
NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that Mark Baker, Chief Executive Officer, will present at two upcoming investor